Home › Pharmacology › Alpha, Beta-Blockers

Alpha and Beta-Blockers

Q: What side effects are characteristic of alpha- and beta-blockers?

Common adverse effects include: Hypotension — most likely with carvedilol due to $\alpha$-receptor blockade.Fluid retention and worsening heart failure — fluid retention occurs on days 3–5, and symptoms of heart failure may worsen during the first 1–2 weeks of therapy.Rhythm and conduction disturbances — bradycardia and atrioventricular (AV) block.

Q: What are the absolute contraindications to prescribing carvedilol?

Absolute contraindications include: Bronchial asthma.2nd and 3rd degree atrioventricular (AV) block — in the absence of a functioning pacemaker.Sick sinus syndrome (SSS).Pronounced bradycardia — less than 50 beats per minute.

For medical students2 min readUpdated 2026-10-10

Alpha- and beta-blockers are mixed-action pharmacological agents that simultaneously affect the vascular bed, heart, and kidneys. Through combined receptor blockade, they effectively lower blood pressure while preventing unwanted reflex tachycardia.

Representative drugsCarvedilol and labetalol

TargetsSelective alpha-1 and non-selective beta-receptors

HemodynamicsBlood pressure reduction without reflex tachycardia

KidneysInhibition of renin production and secretion

Mechanism of Combined Action

Alpha- and beta-blocker drugs represent a class of pharmacological agents with a unique dual mechanism. Unlike narrow-spectrum drugs, these active substances work on multiple physiological targets simultaneously.

The main pharmacodynamic feature is combined receptor blockade:

Selective blockade of $\alpha_1$-adrenergic receptors: provides targeted action on blood vessels.
Non-selective blockade of $\beta$-adrenergic receptors: exerts systemic effects on the myocardium and renal tissue.

Thus, mixed adrenergic blockers simultaneously control vascular tone, cardiac output, and the endocrine function of the kidneys.

Pharmacodynamic Effects and Hemodynamic Logic

The drug action follows a strict logical chain leading to the normalization of blood pressure (BP).

Vascular phase: blocking $\alpha_1$-receptors leads to a drop in vascular smooth muscle tone. Vasodilation occurs, which is the primary factor in lowering blood pressure.
Cardiorenal phase: blockade of $\beta$-receptors suppresses cardiac activity (reduced force and rate of contractions). Concurrently, renin secretion decreases in the kidneys—an enzyme that triggers hypertensive cascades.
Final result: normally, sudden vasodilation causes a compensatory increase in heart rate. However, when taking mixed blockers, the reduction in blood pressure occurs without marked reflex tachycardia, because the cardiac $\beta$-receptors are already reliably blocked.

Clinical Features of Group Representatives

In clinical practice, there are two main drugs, each with its own application profile.

Labetalol (Labetalol) Its use depends strictly on the route of administration:

Oral: prescribed for planned, systematic treatment of arterial hypertension.
Intravenous: used in emergency medicine for rapid management of hypertensive crises.

Carvedilol (Carvedilol) In addition to the classical effects of mixed blockade, this drug has important additional properties:

Exhibits pronounced antioxidant activity.
Possesses lipid-lowering effects (improves lipid profile).

Due to these properties, the indications for carvedilol are expanded: it is used not only for hypertension but also serves as a foundational medication for chronic heart failure (CHF).

Frequently asked questions

What side effects are characteristic of alpha- and beta-blockers?

Common adverse effects include:

Hypotension — most likely with carvedilol due to $\alpha$-receptor blockade.
Fluid retention and worsening heart failure — fluid retention occurs on days 3–5, and symptoms of heart failure may worsen during the first 1–2 weeks of therapy.
Rhythm and conduction disturbances — bradycardia and atrioventricular (AV) block.

What are the absolute contraindications to prescribing carvedilol?

Absolute contraindications include:

Bronchial asthma.
2nd and 3rd degree atrioventricular (AV) block — in the absence of a functioning pacemaker.
Sick sinus syndrome (SSS).
Pronounced bradycardia — less than 50 beats per minute.

What are the pharmacokinetics and metabolism features of carvedilol?

Carvedilol is a lipophilic drug, which determines its main pharmacokinetic properties:

Absorption and bioavailability — absorbed well and quickly in the intestine, but has low bioavailability (about 25–50%) due to extensive first-pass hepatic metabolism.
Distribution — characterized by high plasma protein binding.
Metabolism and elimination — metabolized primarily in the liver via the cytochrome P450 isoenzyme system (CYP2D6), with high hepatic clearance.
Dose adjustment — required in liver disease and reduced hepatic blood flow.

Why doesn't reflex tachycardia occur during vasodilation caused by these drugs?

A drop in vascular tone typically causes a compensatory increase in heart rate. However, mixed agents non-selectively block cardiac beta-receptors, blunting this response, so tachycardia does not develop.

How exactly do alpha- and beta-blockers affect renal function?

By blocking beta-adrenergic receptors located in the renal tissue, the drugs reduce renin secretion. This eliminates one of the key drivers of elevated blood pressure.

What is the clinical difference between labetalol dosage forms?

The oral formulation is intended for long-term, routine blood pressure control. Intravenous administration is used exclusively in acute settings for the immediate management of hypertensive emergencies.

What additional properties make carvedilol the drug of choice in heart failure?

Carvedilol has proven antioxidant and lipid-lowering activity. Combined with cardiac depression, this makes it highly effective in treating chronic congestive heart failure.

Go deeper

Hemodynamic mechanisms of reflex tachycardia development
The role of renin in regulating vascular tone and blood pressure
Significance of antioxidant activity in chronic heart failure
Differences between selective and non-selective adrenergic receptor blockade
Pathogenesis of hypertensive crisis and rationale for intravenous therapy